Aiosyn is at the forefront of developing AI-powered pathology solutions specifically tailored for cancer and kidney diseases. Their flagship product, the NephroPath platform, utilizes deep learning techniques to analyze kidney structures and quantify lesions, thereby enhancing the understanding and treatment of renal diseases. Aiosyn's technology is designed to improve clinical workflows by providing data-driven insights that support diagnostic accuracy and research efforts. Their solutions are modular and seamlessly integrate into existing pathology workflows, ensuring that medical professionals can adopt these advanced tools without disrupting their established processes.

In addition to their focus on kidney pathology, Aiosyn has made significant strides in cancer diagnostics, particularly through their AI-powered mitosis detection solutions. These tools aim to enhance the precision of cancer grading and improve the efficiency of clinical pathology operations. Aiosyn's commitment to collaboration with pathologists ensures that their AI algorithms are developed with a deep understanding of clinical needs, ultimately leading to better patient outcomes. Their technology not only aims to streamline research and clinical diagnostics but also seeks to facilitate the identification of novel biomarkers, thereby accelerating drug development and improving treatment strategies in oncology and nephrology.

Netherlands

Aiosyn is a Dutch healthtech company that is developing precision pathology software solutions for breast cancer and chronic kidney disease. 

Aiosyn launched its first automated QC test on the EU market (AiosynQC) and the first clinical diagnostic test for breast cancer is pending regulatory approval in the EU. 

With our NephroPath platform we support CROs and Biopharma with quantifying kidney biomarkers thereby accelerating (pre-)clinical drug development studies.

Aiosyn

Company Details